8-K - Werewolf Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Werewolf Therapeutics announced a 64% workforce reduction and the resignation of its CFO and CMO, resulting in an estimated $4.1 million one-time charge in Q1 2026. The Company appointed Michael Urban as principal financial officer and is evaluating strategic alternatives for its pipeline.

Key Takeaways

1Board approved a reduction in force affecting 64% of the workforce on February 9, 2026.

2Company expects to record a one-time charge of approximately $4.1 million in Q1 2026 for the restructuring.

3CFO Timothy W. Trost and CMO Dr. Randi Isaacs resigned effective February 13, 2026, and will transition to consulting roles.

4Michael Urban was appointed as principal financial officer and principal accounting officer effective February 13, 2026.

5Company is evaluating strategic alternatives, including partnerships for WTX-124 and WTX-330 INDUKINE programs.

Current Report Details

Event Type

Impairment

Management Change

Regulation Fd

Disclosure

Mandatory

Variant

8-K

Items Reported

2.05

Costs Associated with Exit or Disposal Activities. On February 9, 2026, the board of directors (the “Board”) of Werewolf Therapeutics, Inc. (the “Company”) appr

Impairment

$4.1M

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of

Management Change

$250.00

7.01

is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section,

Regulation Fd

Executive & Director Changes

Timothy W. Trost

Chief Financial Officer

Resignation

Effective: 2026-02-13

Part of the Reduction

Dr. Randi Isaacs, M.D.

Chief Medical Officer

Resignation

Effective: 2026-02-13

Part of the Reduction

Michael Urban

Principal Financial Officer and Principal Accounting Officer

Appointment

Effective: 2026-02-13

Succession following resignation

Exhibits (1)

8-K